Lapatinib shows utility for patients with a particularly troublesome form of the cancer
SAN ANTONIO — A recently approved breast cancer drug called lapatinib may serve as a valuable partner for letrozole, a standard frontline drug for the disease, according to a study of patients whose cancer has spread.
Patients with metastatic breast cancer are destined to return to chemotherapy, and this drug combination seems to significantly delay that day for patients who have a certain form of the disease, says medical oncologist Stephen Johnston of the Royal Marsden NHS Foundation Trust in London.
He presented the findings December 11 at the San Antonio Breast Cancer Symposium.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.